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Abstract
Background: FibroTest (FT) is a validated biomarker of fibrosis. To assess the applicability rate and to reduce the
risk of false positives/negatives (RFPN), security algorithms were developed. The aims were to estimate the
prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences.
Methods: Four populations were studied: 954 blood donors (P1), 7,494 healthy volunteers (P2), 345,695
consecutive worldwide sera (P3), including 24,872 sera analyzed in a tertiary care centre (GHPS) (P4). Analytical
procedures of laboratories with RFPN > 5% and charts of P4 patients in with RFPN were reviewed.
Results: The prevalence of RFPN was 0.52% (5/954; 95%CI 0.17-1.22) in P1, 0.51% (38/7494; 0.36-0.70) in P2, and
0.97% (3349/345695; 0.94-1.00) in P3. Three a priori high-risk populations were confirmed: 1.97% in P4, 1.77% in HIV
centre and 2.61% in Sub-Saharan origin subjects. RFPN was mostly associated with low haptoglobin (0.46%), and
high apolipoproteinA1 (0.21%). A traceability study of a P3 laboratory with RFPFN > 5% permitted to correct
analytical procedures.
Conclusion: The mean applicability rate of Fibrotest was 99.03%. Independent factors associated with the high risk
of false positives/negatives were HIV center, subSaharan origin, and a tertiary care reference centre, although the
applicability rate remained above 97%.
Background
Due to the limitations of liver biopsy biomarkers are
widely used as a non-invasive alternative in patients with
chronic liver disease to assess fibrosis stage and necroin-
flammatory activity [1-3]. One of the most validated
serum biomarkers, Fibrotest-Actitest (FT-AT), was intro-
duced on the market in September 2002 and has been
widely prescribed since then [2-4]. The French Heath
Authorities (HAS) have recommended the following pre-
cautions of use for FT: (1) the laboratory that performs
the test must use the appropriate assay technique and
ensure proper quality control (e.g. with regard to sample
storage), and (2) the person who prescribes the test must
consider confounding factors when interpreting test
results. Patients should have no intercurrent illness, in
particular acute inflammation, hemolysis, or Gilbert’s
syndrome, and should be taking no medications that are
known to cause elevated bilirubin levels [3].
The aim of the “precautions of use” is to reduce the
number of false positive/false negative. The purest defi-
nition of false positive/negative for a biomarker of liver
injury can be obtained only by large surgical biopsy
[5,6]. Therefore there is no perfect reference test for the
definition of false positive/negative in a large population.
From several studies of discordances results between
biopsy (the classical reference) and FT, the prevalence of
discordant results is around 25%, half of the cases being
d u et ob i o p s yf a i l u r ea n dh a l fb e i n gd u et oF Tf a i l u r e
[4,5,7-9].
Due to these limitations of the classical definition of
false positive/false negative, we propose to use the con-
cept of “high risk profile of false positive/false negative
results” (RFPN) and to use it for the definition of FT
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recommended pre-analytical and analytical procedures
[10-15].
“Security algorithms” were elaborated in order to
identify subjects with RFPN. These algorithms were
initially derived from the first validation of FT-AT
[8,16-20]. FT-AT are calculated through a centralized
website http://www.biopredictive.com after entering the
results of the panel’s components [4]. Therefore it has
been possible to identify RFPN during this step and the
suspected RFPN components are indicated on the
results sheets.
In order to improve the medical service, the specific
aims of the present study were to estimate the applic-
ability of FT using prevalence of RFPN and of proven
failures, to identify factors associated with their occur-
rence and to identify new causes. The integrated data-
base of 354,143 tests, which is the accumulation of the
first seven years of FT-AT prescription, was used.
Methods
Populations included
Four prospective populations were included (Figure 1):
954 blood donors between January 2003 and March
2004 (P1); 7,494 healthy volunteers from a general
population without previous history of liver disease
between June 2006 and September 2008 (P2); 345,695
consecutive FT-AT (P3) analyzed on the dedicated
website between October 2002 and June 2009, includ-
ing 24,872 patients with clinical characteristics seen in
a tertiary care reference centre, Groupe Hospitalier
Pitié Salpêtrière, Paris, France (reference population
P4), for which the detailed clinical characteristics were
easier to retrieve. The components of FT-AT were
analyzed on fresh samples; the same laboratory (refer-
ence center) was used for P1, P2 and P4; the P3 com-
ponents of FT-AT were analyzed prospectively in 449
labs in 35 countries.
Device description
The FibroTest is comprised of two parts: 1) biomarker
assays (components of the panel) measuring alpha2-
macroglobulin (A2M), apolipoprotein A1 (ApoA1),
haptoglobin, gamma-glutamyl-transpeptidase (GGT)
and total bilirubin (bilirubin); and 2) a software con-
taining a fixed, pre-determined algorithm to generate
the FibroTest score from the components, adjusted for
age and gender.
To be validated and interpretable, the components
assays of FT must follow the pre-analytical and analytical
recommendations: measurements are calibrated and per-
formed according to standardized reagents against refer-
ence materials; expression in multiples of the upper limit
of reference values should not be employed [10-15]; and
company-approved analyzers and kits are used to generate
quantified values of the individual markers [4]. Since the
first study, 157 peer-reviewed publications including sev-
eral meta-analyses, have consistently validated the accu-
racy of FT-AT for assessing the stages of liver fibrosis
when these technical recommendations have been utilized
and when the area under the receiver operating character-
istics curve has been standardized according to stage spec-
trum. [Additional file 1].
Endpoints
The main endpoint was RFPN, the percentage of
patients with values outside the reference ranges (abnor-
mal values) and in whom the switch to the median
value of the given abnormal variation component
induced a variation of at least 0.30 of the FT value. This
variation was considered clinically significant, as a varia-
tion of 0.30 in FT is equivalent to 1.5 histological
METAVIR score of fibrosis [21]. Abnormal values of
each component were defined as those beyond the 98%
percentile of the normal distribution (one lower percen-
tile or one upper percentile). The reference ranges for
each component were established from the normal dis-
tribution observed in the reference laboratory (Biochem-
istry Department, Groupe Hospitalier Pitié Salpêtrière,
Paris France) during the first studies in patients with
HCV [16], HBV [17], alcoholic liver disease [18], and
non-alcoholic fatty liver disease [19] [Additional file 2
Table S1, Additional file 2 Table S2, Additional file 2
Table S3, Additional file 2 Table S4]. These “security”
algorithms were previously validated using analyses of
discordances versus liver biopsy [7] and discordances
with liver stiffness measurements [8,9].
The specificity of FT-AT was checked using the P1
and P2 control populations after the exclusion of cases
with a previous history of liver diseases and exclusion of
RFPN. In these controls, the prevalence of presumed
advanced fibrosis (FT > 0.48, equivalent to METAVIR
stage F2F3F4) or advanced activity (AT > 0.52, equiva-
lent to METAVIR grade A2A3) [21] was assumed to be
lower than 5% in both groups. P2 subjects with FT sug-
gesting advanced fibrosis were prospectively retested in
the reference center [22].
High-risk related factors analyzed
The risk factors associated with RFPN were assessed in
each population. Two categories of factors were consid-
ered: analytical, and non-analytical.
Charts of the RFPN in the P4 group were re-analyzed
retrospectively by three experts (TP, MM and YN) in
order to identify new possible causes of component
errors and to validate the positive predictive value of
high-risk profiles. In each case the cause of failure was
attributed to FT or not according to the a priori (pre-
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fibrosis (METAVIR stage F2F3F4); biopsy was the refer-
ence if performed less than 5 years apart; when no
biopsy had been performed but an LSM was interpreta-
ble (at least 10 measures, success rate greter than 60%
and interquartile range lower than 30%), it was taken as
reference (advanced fibrosis if greater than 7.1 kPa);
when esophageal varices or ascites were present, it was
interpreted as advanced fibrosis; for low haptoglobin, if
there was no reference but a cause of hemolysis was
identified, the FT > = 0.48 was considered a false posi-
tive. When no reference presented with a clear cause of
component error (such as hemolysis for haptoglobin or
severe undernutrition for A2M or ApoA1), the case was
stated to be indeterminate.
Analytical factors
The impact of analytical factors was assessed using three
methods, as performed on the P3.
First, we tested the a priori hypothesis that the analyti-
cal procedures improved with time, with a decrease in
RFPN in the last 3 years of this cohort (median).
Second, we tested the a priori hypothesis that the pre-
valence of RFPN could be lower in laboratories that per-
formed more FTs than those that performed less, the
cut-off being chosen as 10,000 for the 7 years of follow-
up, as these 6 laboratories represented 50% of the over-
all assays.
Thirdly, the analytical procedures of laboratories with
a prevalence of RFPN > 5% were reviewed prospectively
during the follow-up to check whether the pre-analytical
and analytical recommendations had been followed.
Non-analytical factors
Known risk factors were those mentioned by Health
Authorities: acute inflammation, hemolysis, Gilbert’s
syndrome and medications associated with elevated
bilirubin [3]. Suspected risk factors were those men-
tioned in publications: ethnicity, HIV (including chole-
static anti viral drugs), large ascite and undernutrition
[3,4,8,22-24].
We therefore predetermined 3 types of populations
concerning RFPN: a low-risk group (P1 blood donors
and P2 healthy volunteers), an intermediate-risk group
Figure 1 Flow sheet of included populations.
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three high risk groups: tertiary care reference centre
(P4), HIV centre and patients from sub-Saharan origin.
In the P2, P3 and P4 groups, we tested the hypothesis
that component variability could be associated with eth-
nicity. We therefore analyzed the association between
RFPN and the following areas of residency: Western
Europe, the Middle East, Eastern Europe, North Africa,
North America, Central America, and the Far East. In
the P2 group we tested the pre-determined hypothesis
that subjects living in SubSaharan Africa should have an
increased risk of RFPN associated with abnormally low
haptoglobin levels (haptoglobin polymorphism with ana-
haptoglobinemia) [24].
In the P3 group, the impact of coinfection with HIV
was assessed by comparing one center that assess FT-
AT almost exclusively in coinfected patients with HIV
and HCV or HBV with other centers that were not spe-
cialized in HIV [23].
The reference centre is a tertiary care centre where
very high-risk RFPN patients were screened for FT, such
as patients with severe undernutrition and sepsis. In the
P4 group, charts were reviewed for the usual causes of
RFPN: extra-hepatic cholestasis patients (abnormal
increase in GGT and bilirubin); hemolysis (abnormal
decrease in haptoglobin); Gilbert’s syndrome (abnormal
increase in bilirubin); acute inflammation, i.e. acute sep-
sis (abnormal increase in haptoglobin); and severe
undernutrition with total proteins < 50 g/L.
Patients at high-risk related to acute hepatitis were
supposed to be detected by extreme values of ALT,
greater than 622 IU/L (1% upper percentile observed in
first publications), and were excluded in this study,
which focused on chronic liver diseases.
Statistical methods
Comparisons used the Student’st - t e s tf o ru n i v a r i a t e
analysis and logistic regression analysis for multivariate
analysis. NCSS statistical software was used [25].
To reduce the risk of type 1 error due to multiple
testing (five pre-determined risk factors, two covariates,
four populations and five FT components) only p-values
less than or equal to 0.0001 were considered to be sig-
nificant. Multivariate analysis included age and gender
as covariates.
The present study was in compliance with the Helsinki
Declaration, was an epidemiological study, not an inter-
ventional study and did not require the approval of an
ethical committee. For the population 4, patients hospita-
lized in the “Groupe Hospitalier Pitié Salpêtrière”,a n d
for which we looked to the possible causes of false posi-
tives or false negatives, the protocol was recognized as
not interventional by the Ethical Committee (November
25th 2005). All the data were strictly anonymous data,
the database was declared to the French authorities
“Commission Informatique et Liberté”, in accordance
with the French law on information processing,
Results
Populations included
The characteristics of the included populations are given
i nT a b l e1 .A se x p e c t e d ,t h eP 1p o p u l a t i o n ,m a d eu po f
blood donors, was younger than the others. The P2
group, a population representative of the French popula-
tion older than 40 years [22], was older than the P3
group, the worldwide population. The majority of FT-
AT assays were performed in Western Europe (86%),
followed by the Middle East (8.10%). The P4 population,
the reference centre, had more males, more residents of
Western Europe and longer laboratory experience in
FT-AT testing compared with the P3 population.
Normal values
In comparison with initial studies, FT references values
were confirmed in the two populations without a history
of liver disease: the mean FT in P1 = 0.11 (98% percen-
tiles 0.01-0.41); in P2, FT = 0.17 (0.02-0.52). Only 2.75%
(3/109; 95% CI 0.57-7.8) of P2 subjects that were rein-
vestigated for FT > 0.48 were proven to be false positive,
i.e., 0.04% (3/7, 554; 0.01-0.12) proven false positive rate.
Prevalence of RFPN
According to the populations, the prevalence of RFPN
was 0.52% (5/954; 95% CI 0.17-1.22) in P1 and 0.51%
(38/7494; 95% CI 0.36-0.70) in P2 (blood donors and
general population, two usually low-risk populations);
0.97% (3349/345695; 95% CI 0.94-1.00) in P3 (inter-
mediate risk); and 1.97% (491/24872; 95% CI 1.80-2.15)
in P4, a high-risk population (Table 1). This RFPN pre-
valence in P4 was significantly higher (P < 0.0001) than
in the P3 worldwide population, confirming the a priori
high-risk of a tertiary care reference centre. There was
also a higher RFPN prevalence versus P3 (P < 0.0001) in
the two other high-risk populations: in patients of the
HIV centre, the RFPN prevalence was 1.77% (46/2606;
95% CI 1.30-2.35), and in subjects of sub-Saharan origin
it was 2.61% (6/230; 95% CI 0.96-5.59).
RFPN per components
In all populations, low haptoglobin was the most fre-
quent cause of RFPN, ranging from 0.41% to 1.30%.
Blood donors (P1)
Among the five (0.52%) tests with RFPN (Table 1), four
(0.42%) were related to low haptoglobin and one to low
A2M.
General population (P2)
Among the 38 (0.51%) tests with RFPN, 31 (0.41%) were
related to low haptoglobin, five to high ApoA1, two to
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Name of Population P1 Blood donors P2 Healthy volunteers P3 Worldwide patients P4 Reference Center
patients
Consecutive cases (n) 1,037 7,554 361,096 24,872
Included cases (n) n = 954 n = 7,494 n = 345,695 n = 24,872
Age mean year (SD; range) 35.75 (12.24;18-67) 56.97 (6.77; 40-90) 49.73 (13.87; 0-101) 49.36 (13.60;0-101)
Gender
Male 483 (50.63%) 4138 (55.22%) 198612 (57%) 15530 (62.44%)
Female 471 (49.37%) 3356 (44.78%) 147083 (43%) 9342 (37.56%)
Country of residency/ancestry Residency Ancestry Residency Residency
Western Europe 1037 (100%) 6705 (89.47%) 295685 (85.53% 24,872 (100%)
Middle East 0 (0%) 0 (0%) 28001 (8.10%) 0 (0%)
Eastern Europe 0 (0%) 0 (0%) 5209 (1.51%) 0 (0%)
North Africa 0 (0%) 467 (6.23%) 6464 (1.87% 0 (0%)
North America 0 (0%) 0% (0%) 7726 (2.23% 0 (0%)
Central America 0 (0%) 0% (0%) 1436 (0.42%) 0 (0%)
Far East 0 (0%) 92 (1.23%) 993 (0.29%) 0 (0%)
South America 0 (0%) 0% (0%) 181 (0.05%) 0 (0%)
Sub-Saharan Africa 0 (0%) 230 (3.07%) 0 (0%) 0 (0%)
Laboratory experience
> 10,000 tests (n = 6) 954 (100%) 7494 (100%) 143772 (41.49%) 24,872 (100%)
< 10,000 tests (n = 443) 0 (0%) 0 (0%) 201923 (58.41%) 0 (0%)
HIV positive patients
Yes 0 (0%) 2 (0.003%) 2602 (0.75%)
3 NA
Negative 954 (100%) 1012/1014 (13.50%) 0 (0%) NA
Unknown 0 (0%) 6443 (66.50%) 343093 (99.25%) NA
Liver Disease Risk Unknown Only known for high risk
profile
Non Alcoholic Fatty Liver 105 (11.01%) 2930 (39.29%) NA NA
Alcoholic Liver Disease 82 (8.59%) 883 (11.84%) NA NA
NAFLD/ALD 19 (1.99%) 1036 (13.89%) NA NA
Hepatitis C Virus 0 (0%) 31 (0.42%) NA NA
Hepatitis B Virus 0 (0%) 3 (0.04%) NA NA
Other 0 (0%) 2 (0.03%) NA NA
No Risk 748 (78.41%) 2572 (34.49%) NA NA
FibroTest
FibroTest mean (SD; 1%-99%
percentiles)
0.11 (0.08;0.01-0.41) 0.17 (0.12;0.03-0.60) 0.42 (0.27;0.03-0.97) 0.40 (0.28;0.03-0.98)
F0 or F0-F1 908 (95.18%) 6302 (84.09)% 131658 (38.09%) 10526 (42.32%)
F1 or F1-F2 42 (4.40%) 927 (12.37)% 77974 (22.56%) 5302 (21.32%)
F2 0 (0%) 151 (2.01%)
2 31646 (9.15%) 2059 (8.28%)
F3 or F3-F4 3 (0.31%)
1 76 (1.01%)
2 46021(13.31%) 2979 (11.98%)
F4 1 (0.10%)
1 38 (0.51%)
2 58396 (16.89%) 4006 (16.11%)
Actitest
Actitest mean (SD; 1%-99%
percentiles)
0.08 (0.07;0.01-0.40) 0.11 (0.10;0.02-0.52) 0.37 (0.26;0.02-0.95) 0.30 (0.24;0.02-0.93)
A0 or A0-A1 935 (98.01%) 7060 (94.52%) 166068 (48.05%) 14823 (59.72%)
A1 or A1-A2 16 (1.68%) 347 (4.46%) 84102 (24.33%) 5207 (20.98%)
A2 or A2-A3 1 (0.10%) 39 (0.48%) 26714 (7.73%) 1455 (5.86%)
A3 2 (0.21%) 48 (0.64%) 68741 (19.89%) 3334 (13.43%)
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with proven Gilbert’s syndrome.
Worldwide population (P3) (Table 2)
Among the 3,349 (0.97%) tests with RFPN, the most fre-
quent were false positives due to low haptoglobin
(0.46%), false negatives due to high ApoA1 (0.21%), false
positives due to high A2M (0.12%), and false negatives
due to low A2M (0.12%). The prevalence of other RFPN
profiles (low apoA1, high GGT and high bilirubin) all
together was 0.05%. No RFPN were related to high
haptoglobin.
Reference centre patients (P4) (Table 2)
Among the 491 (1.97%) tests with RFPN, the most fre-
quent were due to low haptoglobin (1.30%), and the
others were similar to P3: high ApoA (0.23%), low A2M
(0.22%), low ApoA1 (0.10%), high A2M (0.10%), high
GGT (0.03%), and none for bilirubin.
Factors associated with RFPN
General population (P2)
Sub-Saharan origin was the only factor associated with
false positive due to low haptoglobin in multivariate
analysis (OR = 8.0; 95% CI 3.2-20.0; P < 0.0001).
Worldwide patients (P3)
Factors associated in multivariate analysis with RFPN in
the worldwide population (P3) are described in Table 3.
Low A2M (Table 3 and Additional file 3, Table S5)
There was more risk of false negative in Eastern Europe
residents.
High A2M (Table 3 and Additional file 3, Table S5)
There was more risk of false positives in Eastern Europe
residents.
High Apolipoprotein A1 (Table 3 and Additional file
3, Table S6) Both analytical and non-analytical factors
were associated with a risk of false negative due to high
ApoA1 in multivariate analysis. There was less risk in
subjects assessed in laboratories with more experience,
having performed over 10,000 FT-AT tests. There was
more risk in subjects from the reference centre.
Low ApoA1 (Table 3 and additional file 3, Table S6)
Both analytical and non-analytical factors were asso-
ciated with a risk of false positive due to low ApoA1 in
multivariate analysis. There was more risk in labora-
tories with more experience (over 10,000 FT-ATs) and
in the reference centre.
High GGT (additional file 3, Table S7), or high bilir-
ubin No risk factors were identified for false positive
due to high GGT or high bilirubin.
Low haptoglobin (Table 3 and additional file 3,
Table S7) Both analytical and non-analytical factors
were associated with the risk of false positive due to low
haptoglobin in multivariate analysis. There was less risk
in subjects assessed during the last 3 years of testing in
laboratories with a high level of experience (more than
10,000 FT-AT), and in residents of Western Europe,
North Africa and North America. There was more risk
in HIV co-infected patients and in those from the refer-
ence centre.
Table 2 Prevalence of FibroTest with high-risk profile of false positive/negative (RFPN
1)
Parameters All (P3) n = 345,695 Reference center (P4) n = 24,872
Lower limit and
RFPN n (%)
Upper limit and
RFPN n (%)
Lower limit and
RFPN n (%)
Upper limit and
RFPN n (%)
Haptoglobin g/L 1590 (0.46%)
3 0 (0%)
2 324 (1.30%) 0 (0%)
Apolipoprotein A1 g/L 118 (0.03%)
3 732 (0.21%)
2 25 (0.10%) 57 (0.23%)
Alpha-2 macroglobulin g/L 419 (0.12%)
2 427 (0.12%)
3 54 (0.22%) 24 (0.10%)
GGT IU/L 0 (0%) 78 (0.02%)
3 0 (0%) 8 (0.03%)
Total Bilirubin, μmol/L 0 (0%) 6 (0.001%)
3 0 (0%) 0 (0%)
1Defined as a change > 0.30 in Fibrotest (at least 1.5 fibrosis METAVIR stage) when switching to the median value of the given parameter. Overall at least one
parameter out of limits with significant impact was observed in 3349 cases (0.97%).
2 Risk of false negative
3 Risk of false positive
Table 1 Characteristics of included populations (Continued)
FibroTest-ActiTest
Interpretable 949 (99.48%; 98.78-
99.83)
7456 (99.49%; 99.30-
99.64)
342,346 (99.03%; 99.00-
99.06)
24381 (98.03%; 97.95-98.20)
High risk False Positive/Negative
(95% CI)
5 (0.52%; 0.17-1.22) 38 (0.51%; 0.36-0.70) 3349 (0.97%; 0.94-1.00) 491 (1.97%; 1.80-2.15)
1 All four cases with Fibrotest greater than 0.48 had a high-risk profile of components which were detected by security algorithms (one low A2M and 3 low
haptoglobin).
2 31 cases out of the 265 cases with FibroTest greater than 0.48 had a high-risk profile of components which were detected by security algorithms.
NA = not available
3 Hospital unit with prevalence of HIV > 90%
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RFPN in Eastern Europe residents could be traced to
one lab (#1517). This laboratory had a rise in RFPN pre-
valence from 1/65 (1.54%) in 2005, 12/166 (6.74%) in
2006 and 119/650 (18.31%) in 2007. The cause identified
was an improper calibration that mistakenly settled the
starting-point of the A2M calibration curve. After cor-
rection, the RFPN significantly decreased compared to
previous years (P < 0.001): 58/1340 (4.33%) in 2008 and
26/1295 (2.01%) in 2009.
Reference centre patients (P4) (Table 4)
Out of the 491 RFPN identified in the P4 population,
331 (67%) charts were prospectively reviewed (range 59-
100%). Of these, 118 (36%) were proven false positives
of FT, due to 1) low haptoglobin in 114 (mostly hemoly-
sis) (Table 4 and additional file 4, Table S8); 2) high
GGT in two (chronic pancreatitis) (Table 4 and addi-
tional file 5, Table S9); and 3) low ApoA1 in two (severe
undernutrition) (Table 4 and additional file 5, Table
S10). No specific cause of high A2M was found (addi-
tional file 5, Table S11). There were eight proven false
negatives of FT: 5 due to low A2M (large ascites or
severe undernutrition) (additional file 5, Table S12), and
three due to high ApoA1 (additional file 5, Table S13).
No specific cause of the ApoA1 increase was found, but
two repeated assessments in two patients found a nor-
mal value, suggesting either an unknown transient factor
or an analytical error for the first assay.
In 41/2602 (1.58%) HIV positive patients with hapto-
globin RFPN, 14 (0.54%) were proven false positives, 18
proven true positives (0.69%) and in the remaining 9
(0.35%), the attributability of error was indeterminate.
Biopsies was the reference in 38 cases for suspected
RPFN, including 5 for a FibroTest value stage F1 or F2
and an interval greater than one year between FibroTest
and biopsy. LSM was the reference in 15 cases.
Discussion
The present study assesses the applicability rate of FT-
AT, using the definition of high-risk profiles of false
positive/negative induced by each component. The pre-
valence of the most frequent proven causes of high-risk
profiles was assessed, and new causes of high-risk pro-
files were identified. This study aim was to better define
the applicability of such composite biomarkers. This
study was not designed for the assessment of the classi-
cal false positive/false negative rate. Analysis of discor-
dances between imperfect reference tests should be
Table 3 Factors associated in multivariate analysis with RFPN in the worldwide population (P3)
Low haptoglobin Low ApoA1 High ApoA1 Low A2M High A2M
Risk for FibroTest False Positive False Positive False Negative False Negative False Positive
Number of
patients
1,590 118 732 419 427
Range 0.01-0.08 g/L 0.10-0.41 g/L 2.51-6.97 g/L 0.10-0.80 g/L 5.90-9.68 g/L
Factor (n) Odds Ratio (95% CI) P value
1
Analytical factor
Last 3 years of test 0.76 (0.68-0.84) P < 10
-5 NS NS NS NS
> 10,000 tests 0.44 ((0.39-0.50) P < 10
-5 NS 0.48 ((0.39-0.50) P <
10
-5
NS NS
Non analytical
factor
Residency
Western
Europe
NS NS NS NS NS
North Africa NS NS NS NS NS
North America 0.05 (0.01-0.20) P =
0.00005
NS NS NS NS
Eastern Europe NS NS NS 22.44 (5.55-90.85) P < 10
-
4
NS
HIV center 3.97 (2.88-5.48) P < 10
-5 NS NS NS NS
Age > 50 years 0.63 (0.57-0.70) P < 10
-4 NS 1.86 (1.60-1.86) P <
10
-5
NS 1.56 (1.29-1.90) P =
10
-4
Male gender 1.30 (1.18-1.45) P < 10
-4 NS 0.34 (0.29-0.40) P <
10
-5
2.6 (2.07-3.28) P < 10
-5 NS
Reference center 5.35 (4.67-6.13) P < 10
-5 2.61 (1.66-4.13) P =
0.00003
1.84 (1.39-2.45) P <
10
-5
1.83 (1.36-2.47) P =
0.00008
NS
1 Only odds ratio with P value lower or equal to 0.0001 were considered significant
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Page 7 of 11performed only among applicable results, and this speci-
fic topic has been discussed elsewhere [9]. We acknowl-
edge that there is no ideal rule for the attribution of the
cause of failure. That is why we use the simplest model
one, that is a two classes discordances model, for the
diagnosis of advanced fibrosis versus non advanced
fibrosis with the predetermined standard threshold for
FibroTest, biopsy and LSM. Due to the slow fibrosis
progression rate, the risk of large variability is small in a
two classes model (discordant patients were classified in
a two classes model: F0F1 vs F2F34). Even for a rapid
fibrosis progressor untreated (0.20 METAVIR stage per
year), the mean change in 5 years is 1 stage. Therefore
only patients in those patients stage F1 or in F2 patients
sustained responders with a rapid regression, there was
a risk of discordance due to an interval of 5 years or
greater.”
Applicability
One criteria of efficiency of a diagnostic test is its
applicability, defined as no test failure and reliable
results. In the present study there was no FT failure and
the applicability rate (reliable results) ranged from
99.49% in the general population to 98.03% among
patients of the tertiary care reference centre. In
comparison, the applicability of another validated mar-
ker of fibrosis, elastography, was much lower, with an
81.9% applicability rate assessed in 13,369 examinations,
including 3.1% failure and 15.8% unreliable results [26].
High-risk factors
The usual causes of RFPN were observed [4], but 3 new
items of information were obtained. The RFPN preva-
lence in the general population, as well as their risk fac-
tors, was estimated, and in the reference centre the
prevalence of proven specific causes was assessed.
Haptoglobin
Despite a limited rate (0.46%), low haptoglobin was
clearly the most frequent cause of false positives. A sig-
nificant independent risk (OR = 3.6) of haptoglobin false
positive in patients with HIV was observed. The most
frequent proven causes of low haptoglobin with RFPN
were hemolysis due to cardiac prosthesis 25/114 (22%)
and association with hemoglobin disease in 15/114
(13%), and HIV coinfection in 14/114 (12%).
A very low haptoglobin level had already been
observed prospectively in 249 consecutive samples from
HIV-infected subjects without any known cause of
hemolysis [27] and was significantly associated with
nucleoside analogues treatment. The accuracy of FT for
Table 4 Review of high risk FibroTest using charts in the reference center (P4)
Components of FibroTest
with
high risk profile
Number of
Tests
Identified
Reviewed
(Traceability)
1
Correctly classified Indeterminate Incorrectly classified
True
Positive
True
Negative
False
positive
False
negative
Haptoglobin
< = 0.08 g/L 324 214 (66%) 58 (27%) 0 (0%) 42 (20%) 114 (53%)
2 0 (0%)
> = 3.20 g/L 0 0 (100%) 0 0 0 0 0
Apolipoprotein A1
< = 0.56 g/L 25 17 (68%) 15 (88%) 0 0 (0%) 2 (12%)
3 0 (0%)
> = 2.50 g/L 57 38 (67%) 1 (3%) 30 (79%) 4 (10%) 0 (0%) 3 (8%)
4
Alpha-2 macroglobulin
< = 0.80 g/L 54 32 (59%) 3 (10%) 24 (75%) 0 (0%) 0 (0%) 5 (15%)
5
> = 5.90 g/L 24 24 (100%) 22 (92%) 0 2 (8%) 0 (0%) 0 (0%)
GGT IU/L > = 1140 IU/L 8 6 (75%) 1 (16%) 1 (16%) 2 (33%) 2 (33%)
6 0 (0%)
Total Bilirubin, μmol/L > = 50 0 0 (100%) 0 0 0 0 0
Total 491 331 (67%) 100 (30%) 55 (17%) 50 (14%) 118 (36%) 8 (2%)
1 Inpatients with detailed charts reviewed by 3 experts. (Supplement file S3)
When biopsy was performed (5 years apart) it was taken as a reference; when no biopsy had been performed but an LSM was interpretable it was taken as a
reference (advanced fibrosis if greater than 7.1 kPa); when oesophageal varices or ascites were present it was taken as advanced fibrosis; for low hapto, if no
reference and a cause of hemolysis was identified FT > = 0.48 was considered false positive. When no reference was present without a clear cause of component
error (such as hemolysis for hapto or severe undernutrition for A2M and apoA1, the case was stated to be indeterminate.
2 Low haptoglobin, already known causes: hemolysis with patent cause: cardiac prosthesis (n = 25), drepanocytosis (n = 13), ribavirin (n = 8), thalassemia (n = 2),
autoimmune (n = 2); anahaptoglobinemia (n = 1). Two new possible causes were HIV co-infection (n = 14) and splenectomy (n = 4)
3 Low ApoA1 already known cause: severe undernutrition (n = 2 total serum proteins < = 50 g/L)
4 High ApoA1 suspected analytical error or an unknown transient factor as in 2 cases, 2 repeated ApoA1 assays were in normal range
5 Low A2M already known causes: large ascites (n = 3), severe undernutrition (n = 1 total serum proteins < = 50 g/L); a new possible cause was macrophage
activation syndrome (n = 1)
6 High GGT already known cause: chronic pancreatitis (n = 2)
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Page 8 of 11the diagnosis of fibrosis remained highly significant in
HIV patients coinfected with HCV [28] or HBV [29]
and was similar to non-HIV patients. This is explained
in the present study, as this profile rate which induced a
significant change (more than one METAVIR fibrosis
stage) is rare (1.58%), with only 0.54% proven false
positives.
Only one case of anhaptoglobinemia was identified
with RFPN. FT has not been prescribed widely in West
African countries, a region which may have a higher pre-
valence of anahaptoglobulinemia. However a study in
Burkina Faso did not observe such cases in a validation
study of FT in patients with chronic hepatitis B [30].
Splenectomy was observed in four cases without
other overt causes; we did not find any cases or ratio-
nale in the literature directly linking splenectomy and
haptoglobin levels. The hypothesis could be that of a
confounding disease (hemolytic anemia treated by sple-
nectomy), or the consequences of splenectomy on red
blood cell aging and destruction [31]. Therefore RFPN
can not be directly attributed to splenectomy at this
time. However this should be mentioned in the pre-
cautions of use.
We did not observe any cases of RFPN due to high
haptoglobin, even in the tertiary care reference center.
This is reassuring for patients with associated inflamma-
t o r yd i s e a s ea n dc o n f i r m st h eh i g ha p p l i c a b i l i t yr a t eo f
FT already observed in patients with cryoglobulinemia
and vasculitis [32].
ApoA1
High ApoA1 was the most frequent cause (0.21%) of
false negative risk and was associated with the tertiary
care reference center. The direct causality was uncertain.
Among the three cases that indeed had a false negative
result since advanced fibrosis was proven, the repeated
apoA1 returned to “normal” values in two cases with
true positives of repeated FT, suggesting a transient
unknown factor or an analytical error. Among transient
factors, a dietary cause was not identified, and we had
already observed previously that there were no differ-
ences between fasting and non-fasting results [33].
Low ApoA1 was rarely (0.03%) associated with false
positive risk. The only factor that was identified as being
associated with this profile was the tertiary care refer-
ence center. Most of these patients had severe undernu-
trition with serum total protein concentrations lower
than 50 g/L.
Alpha 2 macroglobulin
The reference center was associated both with false
positive and false negative A2M RFPN results. The
causes of low A2M proven false negatives were patients
with large ascites or severe undernutrition with total
proteins lower than 50 g/L. One new cause was a
proven macrophage activation syndrome with a very
high total protein count (112 g/L). The rationale could
be an increase of IFN gamma [34], which down-regu-
lates the A2M-activated receptor [35].
There were no cases of high A2M with false positive
RFPN which were proven to be true false positives.
Therefore it is possible that this profile could be an
excessive security warning.
GGT
A very low prevalence of elevated GGT RFPN (0.02%)
was observed. In the reference center, the only proven
causes identified were two cases with chronic pancreati-
tis, an already well known cause of FT false positive.
Total bilirubin
The prevalence of bilirubin RFPN was very low, 0.001 in
the worldwide database and none in the reference cen-
ter. Only one case of Gilbert’s syndrome was associated
with a proven false positive among the general popula-
tion. Overt Gilbert’ss y n d r o m eh a sap r e v a l e n c eo f
around 4%, but in the usual range of bilirubin levels,
there was no significant impact on FT presumed fibrosis
stage. These global results are reassuring, with a likely
reliable physician selection for the exclusion of extra-
hepatic cholestatic diseases.
Overall recommendations for precautions of use
As a comparison with the first HAS recommendations
[3], this study estimated the prevalence of the pre-
viously identified intercurrent illnesses acting as con-
founding factors when interpreting test results: 0.46%
for hemolysis, and less than 0.001% for Gilbert’ss y n -
drome. It was reassuring that there were no cases of
acute inflammation identified through extreme values
of haptoglobin or A2M. Despite a still high applicabil-
ity rate, greater than 97%, the following at-risk popula-
tions must be mentioned: HIV infected patients and
those of sub-Saharan origin. The following rare but
proven causes must be added: severe undernutrition,
pancreatitis, and macrophage activation syndrome. In
addition, though it is not proven, splenectomy should
be mentioned.
Conclusion
This type of study should improve the benefit-risk
assessment of non-invasive strategies in the forthcoming
new standards of care of patients with chronic liver dis-
eases [36]. Such studies must be performed in suspected
high-risk populations as well as in apparently healthy
volunteers which are representative of the general popu-
lation. As for the approved drugs’ labeling, the new
diagnostic tests should describe the proven and sus-
pected risk factors of false positive and negative with
estimates of the prevalence of very high risk profiles,
defining not applicable results.
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